Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luveltamab Tazevibulin in Infants and Children With CBFA2T3::GLIS2 AML
NCT06679582Phase 2Terminated
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of luveltamab tazevibulin in acute myeloid leukemia (AML) (2 cohorts), sponsored by Sutro Biopharma, Inc. Primary endpoint: Efficacy of Luveltamab Tazevibulin Monotherapy at 12 weeks. Started Dec 2024; status: terminated.
02
Drugs
luveltamab tazevibulin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06679582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679582.